Today's biggest movers. Our screens cover mega-cap down to micro-cap and surface the catalyst behind the move.
200 articles
Lam Research Corporation (LRCX) rises 5.9% as chip-equipment stocks regain leadership on renewed AI spending optimism. The move appears sector-driven, with Meta’s in-house AI chip plans boosting sentiment across semiconductor equipment names. Lam’s strong earnings track record supports the rally, but valuation remains elevated.
AstraZeneca PLC (AZN) drops sharply after a late-stage Wainua trial miss in ATTR-CM shook investor confidence. The selloff came on above-average volume, signaling a real pipeline repricing rather than routine volatility. Despite the decline, AstraZeneca remains a large, diversified pharma name with solid fundamentals.
Applied Materials, Inc. (AMAT) rises sharply as semiconductor stocks rebound after a sector selloff tied to AI spending worries. The move comes despite no new company-specific catalyst, with investors rotating back into chip names as sentiment improves and AMAT trades near analyst price targets.
PepsiCo, Inc. (PEP) drops after Q2 earnings showed solid revenue growth but weak North American demand. Investors focused on flat snack volumes, a 4% beverage volume decline, and a slight EPS miss, signaling that pricing power is no longer enough to support the stock.
Advanced Micro Devices, Inc. (AMD) rises 7.6% as AI and semiconductor momentum lifts the stock near its 52-week high. A recent Goldman Sachs target hike and solid earnings execution are helping fuel the rally, though valuation remains rich and expectations are elevated.
Micron Technology, Inc. (MU) rises sharply as traders return to memory-chip stocks after a sector selloff. A Samsung profit surge, tight AI memory demand, and Micron’s strong recent earnings helped fuel the rebound, reinforcing the stock’s role as a high-beta AI infrastructure play.
Ionis Pharmaceuticals, Inc. (IONS) slumps after hours after a Phase 3 CARDIO-TTRansform trial miss for eplontersen, also known as WAINUA. The setback dents a key expansion story in ATTR-CM and raises questions about future royalty growth, even as the company remains commercially diversified.
Alnylam Pharmaceuticals, Inc. (ALNY) jumps after hours after a rival ATTR-CM therapy suffered a late-stage trial failure, boosting confidence in Alnylam’s approved treatments. Strong Q1 revenue growth, a solid cash position, and improving sentiment add support to the move.
BridgeBio Pharma, Inc. (BBIO) climbs after hours as a rival ATTR-CM therapy suffers a late-stage setback, improving the outlook for Attruby. The move comes on top of strong sales momentum, fresh financing flexibility, and bullish analyst support, giving the rally more substance than a typical trading pop.
Synchrony Financial (SYF) drops sharply on heavy volume after recent bullish analyst attention, even though the company has strong earnings momentum and a low valuation. The move looks more like a sentiment reset in a credit-sensitive stock than a fresh fundamental setback.
Carlisle Companies Incorporated (CSL) drops after Truist cut its price target on concerns about rising costs and supply chain pressure in commercial roofing. The selloff came on heavier volume, even as the company’s fundamentals remain solid and recent earnings have topped estimates.
QXO, Inc. (QXO) fell sharply as investors reacted to a broader risk-off market and lingering post-acquisition volatility after the TopBuild deal closed. The stock’s above-average volume suggests traders are still repricing the company’s larger, more complex capital structure.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator